“…32,33 As opposed to carbon cage structures, for carboranes manifold achiral, chiral and chiral-at-cage modifications at carbon-as well as at boron-vertices are described in the literature, thus paving the way also for the evaluation and design of target-specific asymmetric drugs. 34,35 While boron-containing drugs like bortezomib, crisaborole and tavaborole are established therapeutics, carborane drugs are still scarce in clinical trials. 30,36,37,38 Within this branch, a limited number of boron-containing HDACis have been investigated.…”